International Clinics
Daily
FDA expands Anktiva approval to papillary-only BCG-unresponsive bladder cancer
On 14 October 2026 the FDA expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln) with BCG for non-muscle invasive bladder cancer.